Accent Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.35M Sell
5,294
-328
-6% -$335K 2.74% 10
2026
Q1
$5.17M Sell
5,622
-96
-2% -$97.3K 2.51% 10
2025
Q4
$6.15M Sell
5,718
-96
-2% -$91.8K 2.64% 9
2025
Q3
$4.44M Buy
5,814
+67
+1% +$49.9K 1.86% 13
2025
Q2
$4.48M Sell
5,747
-66
-1% -$51.3K 2% 12
2025
Q1
$4.8M Sell
5,813
-73
-1% -$60.7K 2.77% 10
2024
Q4
$4.54M Buy
5,886
+3,690
+168% +$3.06M 2.59% 10
2024
Q3
$1.95M Sell
2,196
-790
-26% -$710K 1.12% 16
2024
Q2
$2.7M Buy
2,986
+12
+0.4% +$9.6K 1.66% 14
2024
Q1
$2.31M Buy
2,974
+171
+6% +$122K 2% 12
2023
Q4
$1.63M Buy
+2,803
New +$1.64M 1.29% 17

Other funds holding LLY

Accent Capital Management's LLY Position: Q2 2026 in Review

Accent Capital Management reduced its Eli Lilly (LLY) stake by 5.8% in Q2 2026, selling an estimated $335K and leaving 5,294 shares worth $6.35M. The position accounts for 2.74% of the portfolio, ranked #10.

Accent Capital Management first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Accent Capital Management held 5,294 shares of Eli Lilly worth $6.35M as of Q2 2026.
  • Accent Capital Management sold 328 Eli Lilly shares in Q2 2026, an estimated $335K.
  • Eli Lilly made up 2.74% of Accent Capital Management's portfolio in Q2 2026, its #10 holding.
  • Accent Capital Management first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.